NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

FBLG

FibroBiologics Inc

Jul 11 • 04:00PM ET

0.6293

Dollar change -0.0197
Percentage change -3.04	%

Healthcare • Biotechnology • USA • NASD

Peers: JNJ MRK PFE GILD LLY BMY AMGN REGN VRTX BIIB

| Held by: VTI VXF VTWO IWC IWM VTWG IWO MSSM VTHR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.21	Insider Own	28.35%	Shs Outstand	37.74M	Perf Week	2.83%
Market Cap	24.08M	Forward P/E	-	EPS next Y	-0.52	Insider Trans	0.18%	Shs Float	27.42M	Perf Month	-32.77%
Enterprise Value	22.53M	PEG	-	EPS next Q	-0.12	Inst Own	16.80%	Short Float	2.74%	Perf Quarter	-25.96%
Income	-7.67M	P/S	-	EPS this Y	-37.25%	Inst Trans	8.52%	Short Ratio	2.20	Perf Half Y	-72.15%
Sales	0.00M	P/B	10.10	EPS next Y	-10.71%	ROA	-67.18%	Short Interest	0.75M	Perf YTD	-68.54%
Book/sh	0.06	P/C	2.78	EPS next 5Y	-12.57%	ROE	-559.73%	52W High	5.62 -88.80%	Perf Year	-87.24%
Cash/sh	0.23	P/FCF	-	EPS past 3/5Y	-91.03% -	ROIC	-238.48%	52W Low	0.58 7.89%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.55% 9.07%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.14	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	37.71	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.14	EPS Q/Q	47.64%	SMA20	-8.50%	Beta	-0.79	Target Price	10.67
Payout	-	Debt/Eq	3.03	Sales Q/Q	-	SMA50	-21.85%	Rel Volume	0.91	Prev Close	0.65
Employees	13	LT Debt/Eq	0.37	Earnings	May 28	SMA200	-62.56%	Avg Volume	341.81K	Price	0.63
IPO	Jan 31, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-12.00% -	Trades		Volume	310,197	Change	-3.04%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-24	Initiated	Rodman & Renshaw	Buy	$12
Oct-30-24	Initiated	H.C. Wainwright	Buy	$12
Sep-24-24	Initiated	Maxim Group	Buy	$12

Jul-11-25 08:30AM	FibroBiologics to Present at the Advanced Wound Care Summit USA (GlobeNewswire)
Jul-09-25 08:30AM	FibroBiologics Confirms Ability to Manufacture CybroCell for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank (GlobeNewswire) +9.04%
Jul-07-25 04:35PM	FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10 (GlobeNewswire)
Jun-16-25 04:35PM	FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing (GlobeNewswire) -5.48%
09:50AM	FibroBiologics to Present at the BIO International Convention 2025 (GlobeNewswire)
08:30AM	Loading…
Jun-09-25 08:30AM	FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer (GlobeNewswire)
May-16-25 08:30AM	FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting (GlobeNewswire) -8.42%
May-14-25 04:30PM	FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +22.67%
Apr-29-25 09:15AM	FibroBiologics Presents at the ThymUS 2025 Meeting (GlobeNewswire) -8.37%
09:15AM	FibroBiologics Presenting at the ThymUS 2025 Meeting (GlobeNewswire)
Apr-11-25 08:30AM	FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean (GlobeNewswire) +9.50%
Apr-08-25 08:30AM	FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics (GlobeNewswire) -6.31%
Apr-02-25 08:30AM	FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair (GlobeNewswire) +8.88%
Mar-31-25 04:25PM	FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.26%
Mar-27-25 08:30AM	FibroBiologics Announces 2025 Annual Meeting of Stockholders (GlobeNewswire)
08:30AM	Loading…
Mar-21-25 08:30AM	FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting (GlobeNewswire) +7.77%
Mar-14-25 08:35AM	Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Mar-12-25 01:12PM	Life Sciences Investor Forum Agenda Announced for March 13th (GlobeNewswire)
Mar-04-25 08:30AM	FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics (GlobeNewswire) +6.99%
Feb-27-25 08:30AM	FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic (GlobeNewswire)
Feb-05-25 09:15AM	FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates (GlobeNewswire) +6.45%
Dec-30-24 04:30PM	FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing (GlobeNewswire) -5.08% -10.71%
02:12PM	D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing (GlobeNewswire)
Dec-23-24 07:55AM	FibroBiologics Announces $25 Million Financing (GlobeNewswire) -6.67%
Nov-19-24 09:15AM	FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly (GlobeNewswire)
Nov-14-24 09:15AM	FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics (GlobeNewswire) -8.77%
Nov-12-24 04:20PM	FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -8.12%
Oct-29-24 09:15AM	FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology (GlobeNewswire)
Oct-28-24 09:31AM	FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024 (GlobeNewswire)
Oct-21-24 07:45AM	FibroBiologics and Charles River link for chronic disease therapies manufacture (Pharmaceutical Technology) -9.88%
08:30AM	Loading…
Oct-18-24 08:30AM	FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases (GlobeNewswire)
Oct-16-24 09:15AM	FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office (GlobeNewswire) +17.82%
Oct-11-24 09:31AM	FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit (GlobeNewswire) +12.07%
Sep-30-24 09:31AM	FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-19-24 09:31AM	FibroBiologics Engages Southern Star Research as CRO in Australia (GlobeNewswire)
Sep-12-24 09:31AM	FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology (GlobeNewswire) -7.60%
Sep-06-24 09:31AM	FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) +12.37%
Aug-20-24 09:31AM	FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology (GlobeNewswire)
Aug-07-24 06:52PM	FibroBiologics Files 2024 Second Quarter Report (GlobeNewswire) -39.41%
Jul-15-24 09:31AM	FibroBiologics to Present at JonesTrading Healthcare Summit 2024 (GlobeNewswire) +5.49%
Jun-25-24 09:31AM	FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology (GlobeNewswire)
Jun-13-24 09:31AM	FibroBiologics Set to Join Russell 2000 Index (GlobeNewswire) -6.14%
Jun-06-24 09:31AM	FibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024 (GlobeNewswire) +53.88%
May-15-24 04:30PM	FibroBiologics Announces 2024 Annual Meeting of Stockholders (GlobeNewswire)
09:54AM	FBLG Stock Earnings: FibroBiologics, Inc. - Common Stock Reported Results for Q1 2024 (InvestorPlace)
May-14-24 05:24PM	FibroBiologics Files 2024 First Quarter Report (GlobeNewswire) +10.35%
May-07-24 09:31AM	FibroBiologics to Present at the BIO International Convention 2024 (GlobeNewswire) +5.49%
Apr-25-24 08:00AM	FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids (GlobeNewswire)
Apr-11-24 09:31AM	FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office (GlobeNewswire)
Apr-04-24 09:31AM	FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA (GlobeNewswire)
Mar-28-24 09:31AM	FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus (GlobeNewswire) -8.00%
Mar-19-24 09:31AM	FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment (PR Newswire) +21.36%
Mar-13-24 09:31AM	FibroBiologics to Present at Advanced Wound Care Summit USA (PR Newswire) -5.83%
Mar-06-24 09:31AM	FibroBiologics Appoints Ruben A. Garcia as General Counsel (PR Newswire)
Feb-29-24 05:44PM	FibroBiologics Files 2023 Form 10-K Annual Report (PR Newswire)
Feb-20-24 09:31AM	FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum (PR Newswire) -8.52%
Feb-13-24 09:31AM	FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases (PR Newswire) +88.38%
Feb-08-24 09:31AM	FibroBiologics Announces Three United States Patents for Fibroblast Technology (PR Newswire) -9.91%
Feb-06-24 09:31AM	FibroBiologics Announces Three Japanese Patents on Fibroblast Technology (PR Newswire) -28.26%
Jan-31-24 10:00AM	FibroBiologics Announces Direct Listing on NASDAQ Under the Stock Ticker FBLG (PR Newswire)

FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm's product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O'Heeron on April 8, 2021 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Khoja Hamid	Chief Scientific Officer	May 27 '25	Buy	0.84	20,000	16,800	31,250	May 27 05:56 PM
O'HEERON PETE	Chief Executive Officer	Aug 12 '24	Buy	1.91	8,500	16,269	6,056,647	Aug 12 09:58 PM
Khoja Hamid	Chief Scientific Officer	Aug 12 '24	Buy	1.90	10,000	19,000	11,250	Aug 12 09:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FBLG

FibroBiologics Inc

Upgrade your FINVIZ experience